Metabolomics for Biomarker Discovery: Moving to the Clinic

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Zhang, Aihua ^a   Sun, Hui ^a   Yan, Guangli ^a   Wang, Ping ^a   Wang, Xijun ^a  

^a HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLADENOSINE; ACYLCARNITINE; AMINO ACID; BILE ACID; BIOLOGICAL MARKER; CARBOXYLIC ACID; CARNITINE; CITRIC ACID; CYSTEINE; EPITESTOSTERONE; ETHER PHOSPHOLIPID; FATTY ACID; GLYCOCHENODEOXYCHOLIC ACID; GLYCODEOXYCHOLIC ACID; GLYCOLIC ACID; LYSOPHOSPHATIDYLCHOLINE; METHIONINE; NUCLEOSIDE; NUCLEOTIDE; PENTOSE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SPHINGOMYELIN; STEROL; TRYPTOPHAN; TYROSINE;

ALZHEIMER DISEASE; CANCER PROGNOSIS; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; ENDOMETRIOSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER STAGNATION AND SPLEEN DEFICIENCY SYNDROME; MALIGNANT PLEURA EFFUSION; MASS SPECTROMETRY; METABOLITE; METABOLOME; METABOLOMICS; METASTATIC COLORECTAL CANCER; MILD COGNITIVE IMPAIRMENT; MOLECULAR WEIGHT; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PREGNANCY DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; SPLEEN DISEASE; TREATMENT RESPONSE; MEDICAL RESEARCH;

BIOMARKERS; BIOMEDICAL RESEARCH; HUMANS; METABOLOMICS;

EID: 84930958582     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/354671     Document Type: Review

References (43)

1. M. Tomita and K. Kami, Systems biology, metabolomics, and cancer metabolism, Science, vol. 336, no. 6084, pp. 990-991, 2012.
2. A. Zhang, H. Sun, and X. Wang, Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment, Applied Biochemistry and Biotechnology, vol. 168, no.6,pp. 1718-1727, 2012.
3. H. Tsutsui, T. Maeda, J. Z. Min et al., Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra-performance liquid chromatography with electrospray ionization time-offlight mass spectrometry, Clinica Chimica Acta, vol. 412, no. 11-12, pp. 861-872, 2011.
4. A. Zhang, H. Sun, G. Yan, P. Wang, Y. Han, and X. Wang, Metabolomics in diagnosis and biomarker discovery of colorectal cancer, Cancer Letters, vol. 345, no. 1, pp. 17-20, 2014.
5. J. A. Haviland, M. Tonelli, D. T. Haughey, W. P. Porter, and F. M. Assadi-Porter, Novel diagnostics of metabolic dysfunction detected in breath and plasma by selective isotope-assisted labeling, Metabolism: Clinical and Experimental, vol. 61, no. 8, pp. 1162-1170, 2012.
6. L. Tenori, C. Oakman, W. M. Claudino et al., Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a Pilot Study,MolecularOncology, vol. 6, no. 4, pp. 437-444, 2012.
7. M. Yoshida, N. Hatano, S. Nishiumi et al., Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry, Journal of Gastroenterology, vol. 47, no. 1, pp. 9-20, 2012.
8. A. Zhang, H. Sun, X.Wu, and X.Wang, Urine metabolomics, Clinica Chimica Acta, vol. 414, pp. 65-69, 2012.
9. A. K. Arakaki, J. Skolnick, and J. F. McDonald, Marker metabolites can be therapeutic targets as well, Nature, vol. 456, no. 7221, p. 443, 2008.
10. T. Zhang, X. Wu, M. Yin et al., Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry, Clinica Chimica Acta, vol. 413, no. 9-10, pp. 861-868, 2012.
11. A. Zhang, H. Sun, Y. Han et al., Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach, Analyst, vol. 137, no. 18, pp. 4200-4208, 2012.
12. M. Yuan, S. B. Breitkopf, X. Yang, and J. M. Asara, A positive/ negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue, Nature Protocols, vol. 7, no. 5, pp. 872-881, 2012.
13. J. K. Nicholson and I. D. Wilson, Understanding global systems biology: metabonomics and the continuum of metabolism, Nature Reviews Drug Discovery, vol. 2, no. 8, pp. 668-676, 2003.
14. F. Chen, J. Xue, L. Zhou, S. Wu, and Z. Chen, Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/ mass spectrometry-based metabonomic method, Analytical and Bioanalytical Chemistry, vol. 401, no. 6, pp. 1899-1904, 2011.
15. H. M. Woo, K. M. Kim,M. H. Choi et al., Mass spectrometry based metabolomic approaches in urinary biomarker study of womens cancers, Clinica Chimica Acta, vol. 400, no. 1-2, pp. 63-69, 2009.
16. A. D. Patterson, O.Maurhofer, D. Beyoglu et al., Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling, Cancer Research, vol. 71, no. 21, pp. 6590-6600, 2011.
17. E. Holmes, R. L. Loo, J. Stamler et al., Human metabolic phenotype diversity and its association with diet and blood pressure, Nature, vol. 453, no. 7193, pp. 396-400, 2008.
18. T. J.Wang, M. G. Larson, R. S. Vasan et al., Metabolite profiles and the risk of developing diabetes, Nature Medicine, vol. 17,no. 4, pp. 448-453, 2011.
19. S. F. Graham, O. P. Chevallier, D. Roberts, C. H?lscher, C. T. Elliott, and B. D. Green, Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimers disease, Analytical Chemistry, vol. 85, no. 3, pp. 1803-1811, 2013.
20. C. Ibáñez, C. Simó, P. J. Martí-Álvarez et al., Toward a predictive model ofAlzheimers disease progression using capillary electrophoresis-mass spectrometry metabolomics, Analytical Chemistry, vol. 84, no. 20, pp. 8532-8540, 2012.
21. M. Mapstone, A. K. Cheema, M. S. Fiandaca et al., Plasma phospholipids identify antecedent memory impairment in older adults, Nature Medicine, vol. 20, no. 4, pp. 415-418, 2014.
22. J. F. Xiao, R. S. Varghese, B. Zhou et al., LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort, Journal of Proteome Research, vol. 11, no. 12, pp. 5914-5923, 2012.
23. B. Wang, D. Chen, Y. Chen et al., Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry, Journal of Proteome Research, vol. 11, no. 2, pp. 1217-1227, 2012.
24. Y. Tan, P. Yin, L. Tang et al., Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis, Molecular & Cellular Proteomics, vol. 11, no. 2, Article ID M111.010694, 2012.
25. T. Chen, G. Xie, X. Wang et al., Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma,Molecular & Cellular Proteomics, vol. 10, no. 7, 2011.
26. Y. Shao, B. Zhu, R. Zheng et al., Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery, Journal of Proteome Research, 2014.
27. W. Dai, P. Yin, P. Chen et al., Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis, Analytical and Bioanalytical Chemistry, vol. 406, no. 18, pp. 4325-4335, 2014.
28. S. Qi, X. Ouyang, L. Wang, W. Peng, J. Wen, and Y. Dai, A pilotmetabolic profiling study in serumof patients with chronic kidney disease based on 1H-NMR-spectroscopy, Clinical and Translational Science, vol. 5, no. 5, pp. 379-385, 2012.
29. Y. Y. Zhao, Metabolomics in chronic kidney disease, Clinica Chimica Acta, vol. 422, pp. 59-69, 2013.
30. K. Vouk, N. Hevir, M. Ribi?c-Pucelj et al., Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis, Human Reproduction, vol. 27, no. 10, pp. 2955-2965, 2012.
31. I. Bertini, S. Cacciatore, B. V. Jensen et al., Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer, Cancer Research, vol. 72, no. 1, pp. 356-364, 2012.
32. L. Lin, Z. Huang, Y. Gao, X. Yan, J. Xing, and W. Hang, LCMS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery, Journal of Proteome Research, vol. 10, no. 3, pp. 1396-1405, 2011.
33. J. Jung, S.-H.Kim, H.-S. Lee et al., Serummetabolomics reveals pathways and biomarkers associated with asthma pathogenesis, Clinical and Experimental Allergy, vol. 43, no. 4, pp. 425-433, 2013.
34. J. Xu, Y. Chen, R. Zhang et al., Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers,Molecular & Cellular Proteomics, vol. 12, no. 5, pp. 1306-1318, 2013.
35. C.-W. Lam and C.-Y. Law, Untargeted mass spectrometrybased metabolomic profiling of pleural effusions: fatty acids as novel cancer biomarkers for malignant pleural effusions, Journal of Proteome Research, vol. 13,no. 9, pp.4040-4046, 2014.
36. J. V. de Seymour, C. A. Conlon, K. Sulek et al., Early pregnancy metabolite profiling discovers a potential biomarker for the subsequent development of gestational diabetes mellitus, Acta Diabetologica, vol. 51, no. 5, pp. 887-890, 2014.
37. A. Zhang, H. Sun, and X. Wang, Serum metabolomics as a novel diagnostic approach for disease: a systematic review, Analytical and Bioanalytical Chemistry, vol. 404, no.4,pp. 1239-1245, 2012.
38. A. Zhang, H. Sun, G. Yan, Y. Han, Y. Ye, and X. Wang, Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquidchromatography coupled with high-definition mass spectrometry, Clinica Chimica Acta, vol. 418, pp. 86-90, 2013.
39. H. Sun, A. Zhang, G. Yan et al., Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews, Molecular and Cellular Proteomics, vol. 12, no. 3, pp. 710-719, 2013.
40. X.Wang, A. Zhang, Y. Han et al., Urine metabolomics analysis for biomarker discovery and detection of Jaundice syndrome in patients with liver disease, Molecular and Cellular Proteomics, vol. 11, no. 8, pp. 370-380, 2012.
41. A.-H. Zhang, H. Sun, S. Qiu, and X.-J.Wang, Metabolomics in noninvasive breast cancer, Clinica Chimica Acta, vol. 424, pp. 3-7, 2013.
42. I. Rowe, M. Chiaravalli, V. Mannella et al., Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy, Nature Medicine, vol. 19, no. 4, pp. 488-493, 2013.
43. A. Zhang, H. Sun, and X. Wang, Urinary metabolic profiling of rat models revealed protective function of scoparone against alcohol induced hepatotoxicity, Scientific Reports, vol. 4, article 6768, 2014.